S&P 500   4,554.89
DOW   35,416.98
QQQ   390.19
Alibaba is down more than 10% since earnings, now what?
Secure your stake in the Smart Home industry. (Ad)
5 stocks for the Christmas wishlist: Hoping for a pullback
Teva Pharma is the way to play the re-rise of generic drugs
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Lemonade nears breakout, short interest surges, analysts bearish
ULTA stock is setting up to swing for the fences
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Get ready for Christmas shopping-sprees with these 2 winners
Li Auto smashes estimates proving EVs can be profitable
S&P 500   4,554.89
DOW   35,416.98
QQQ   390.19
Alibaba is down more than 10% since earnings, now what?
Secure your stake in the Smart Home industry. (Ad)
5 stocks for the Christmas wishlist: Hoping for a pullback
Teva Pharma is the way to play the re-rise of generic drugs
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Lemonade nears breakout, short interest surges, analysts bearish
ULTA stock is setting up to swing for the fences
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Get ready for Christmas shopping-sprees with these 2 winners
Li Auto smashes estimates proving EVs can be profitable
S&P 500   4,554.89
DOW   35,416.98
QQQ   390.19
Alibaba is down more than 10% since earnings, now what?
Secure your stake in the Smart Home industry. (Ad)
5 stocks for the Christmas wishlist: Hoping for a pullback
Teva Pharma is the way to play the re-rise of generic drugs
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Lemonade nears breakout, short interest surges, analysts bearish
ULTA stock is setting up to swing for the fences
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Get ready for Christmas shopping-sprees with these 2 winners
Li Auto smashes estimates proving EVs can be profitable
S&P 500   4,554.89
DOW   35,416.98
QQQ   390.19
Alibaba is down more than 10% since earnings, now what?
Secure your stake in the Smart Home industry. (Ad)
5 stocks for the Christmas wishlist: Hoping for a pullback
Teva Pharma is the way to play the re-rise of generic drugs
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Lemonade nears breakout, short interest surges, analysts bearish
ULTA stock is setting up to swing for the fences
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Get ready for Christmas shopping-sprees with these 2 winners
Li Auto smashes estimates proving EVs can be profitable

Kinnate Biopharma Stock Price, News & Analysis (NASDAQ:KNTE)

$2.17
-0.06 (-2.69%)
(As of 11/28/2023 ET)
Compare
Today's Range
$2.15
$2.28
50-Day Range
$1.07
$2.50
52-Week Range
$1.04
$8.31
Volume
606,718 shs
Average Volume
551,230 shs
Market Capitalization
$102.23 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$14.60

Kinnate Biopharma MarketRank™ Stock Analysis

Analyst Rating
Hold
2.20 Rating Score
Upside/​Downside
572.8% Upside
$14.60 Price Target
Short Interest
Bearish
5.38% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.81
Upright™ Environmental Score
News Sentiment
1.55mentions of Kinnate Biopharma in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($2.50) to ($1.31) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.43 out of 5 stars

Medical Sector

210th out of 949 stocks

Pharmaceutical Preparations Industry

84th out of 434 stocks


KNTE stock logo

About Kinnate Biopharma Stock (NASDAQ:KNTE)

Kinnate Biopharma Inc., a clinical-stage oncology company, focuses on the discovery and development of small molecule kinase inhibitors to treat genomically defined cancers in the United States. The company develops KIN-2787, a rapidly accelerated fibrosarcoma inhibitor for the treatment of patients with lung cancer, melanoma, and other solid tumors; KIN-3248 small-molecule kinase inhibitors that target cancer-associated alterations in fibroblast growth factor receptors FGFR2 and FGFR3 genes; and small molecule research programs, including Cyclin-Dependent Kinase 12(CDK12) inhibitor in its KIN004 program. The company was incorporated in 2018 and is headquartered in San Francisco, California. Kinnate Biopharma Inc. is a former subsidiary of Fount Therapeutics, LLC.

KNTE Stock Price History

KNTE Stock News Headlines

Secure your stake in the Smart Home industry.
Last chance to invest in RYSE – the shade automation technology launching in over 100 Best Buy stores this month.
Secure your stake in the Smart Home industry.
Last chance to invest in RYSE – the shade automation technology launching in over 100 Best Buy stores this month.
Wedbush Downgrades Kinnate Biopharma (KNTE)
Kinnate Biopharma (KNTE) Receives a Buy from H.C. Wainwright
KRBP Kiromic BioPharma, Inc.
Expert Ratings for Kinnate Biopharma
See More Headlines
Receive KNTE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Kinnate Biopharma and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
5/11/2023
Today
11/28/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
3/20/2024

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:KNTE
Fax
N/A
Employees
84
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$14.60
High Stock Price Target
$26.00
Low Stock Price Target
$4.00
Potential Upside/Downside
+572.8%
Consensus Rating
Hold
Rating Score (0-4)
2.20
Research Coverage
5 Analysts

Profitability

Net Income
$-116,270,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$5.06 per share

Miscellaneous

Free Float
27,467,000
Market Cap
$102.23 million
Optionable
Not Optionable
Beta
0.33
Beginner's Guide to Pot Stock Investing Cover

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report














KNTE Stock Analysis - Frequently Asked Questions

Should I buy or sell Kinnate Biopharma stock right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Kinnate Biopharma in the last twelve months. There are currently 4 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" KNTE shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in KNTE, but not buy additional shares or sell existing shares.
View KNTE analyst ratings
or view top-rated stocks.

What is Kinnate Biopharma's stock price target for 2024?

5 Wall Street analysts have issued twelve-month price targets for Kinnate Biopharma's stock. Their KNTE share price targets range from $4.00 to $26.00. On average, they anticipate the company's share price to reach $14.60 in the next twelve months. This suggests a possible upside of 572.8% from the stock's current price.
View analysts price targets for KNTE
or view top-rated stocks among Wall Street analysts.

How have KNTE shares performed in 2023?

Kinnate Biopharma's stock was trading at $6.10 at the beginning of the year. Since then, KNTE shares have decreased by 64.4% and is now trading at $2.17.
View the best growth stocks for 2023 here
.

When is Kinnate Biopharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 20th 2024.
View our KNTE earnings forecast
.

How were Kinnate Biopharma's earnings last quarter?

Kinnate Biopharma Inc. (NASDAQ:KNTE) issued its earnings results on Thursday, May, 11th. The company reported ($0.73) EPS for the quarter, meeting the consensus estimate of ($0.73).

When did Kinnate Biopharma IPO?

(KNTE) raised $170 million in an initial public offering (IPO) on Thursday, December 3rd 2020. The company issued 10,000,000 shares at a price of $16.00-$18.00 per share. Goldman Sachs, SVB Leerink, Piper Sandler and Wedbush PacGrow served as the underwriters for the IPO.

Who are Kinnate Biopharma's major shareholders?

Kinnate Biopharma's stock is owned by many different retail and institutional investors. Top institutional shareholders include Lynx1 Capital Management LP (4.24%), Acadian Asset Management LLC (1.56%), Jacobs Levy Equity Management Inc. (0.95%), Citigroup Inc. (0.89%), Rock Springs Capital Management LP (0.86%) and GSA Capital Partners LLP (0.79%). Insiders that own company stock include Carl L Gordon, James B Tananbaum, Orbimed Advisors Llc and Richard Thomas Williams.
View institutional ownership trends
.

How do I buy shares of Kinnate Biopharma?

Shares of KNTE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:KNTE) was last updated on 11/29/2023 by MarketBeat.com Staff

My Account -